Title: P126 <break /> Oral treatment with PBI-4050 ameliorates bleomycin-induced pulmonary fibrosis by reducing serum and lung anti-inflammatory/fibrotic biomarkers.
Abstract: PBI-4050 is a first-in-class orally active compound which displays antifibrotic activities in kidney, heart, liver, pancreas and lung models. PBI-4050 was found to be safe and well tolerated in healthy volunteers and in patients with CKD and Type 2 diabetes without any SAEs. Translation of pharmacological efficacy in humans …